Tocilizumab has a good long-term safety profile,[50,51] but variousadverse effects have been attributed to it including infections,cytopenia and neutropenia, hyperlipidaemia and abnormal liverenzymes.[50,52,54] The neutropenia associated with IL-6R inhibitiondoes not appear to be associated with a risk of severe infection.[51,52]. The gene discussed is IL6R; the disease is neutropenia.